Singapore markets close in 7 hours 15 minutes

Straits Times Index
3,307.83
-6.22(-0.19%)
Nikkei
39,218.79
+149.11(+0.38%)
Hang Seng
19,435.48
-200.74(-1.02%)
FTSE 100
8,424.20
+3.94(+0.05%)
Bitcoin USD
71,005.94
+4,633.01(+6.98%)
CMC Crypto 200
1,506.32
+151.91(+11.20%)

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD

Add to watchlist

130.99

-0.20

(-0.15%)

At close: 04:00PM EDT

131.05

+0.06

(+0.05%)

After hours:

07:59PM EDT

Trade prices are not sourced from all markets

Press releases

Business Wire
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
Business Wire
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
CNW Group
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with gemcitabine-based chemotherapy, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC). This approval is based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant and clinically meaningful improvem